Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of bacterial infection worldwide
3.2.1.2 Growing R&D activities in pharmaceutical companies
3.2.1.3 Growing demand for combination antibiotic therapies
3.2.1.4 Supportive government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with the use of sulfa drugs
3.2.2.2 Availability of alternative antibiotics
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porters analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Oral
5.3 Topical
5.4 Other routes of administration
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Skin infection
6.3 Gastrointestinal (GIT) infection
6.4 Urinary tract infection (UTI)
6.5 Respiratory tract infection (RTI)
6.6 Other applications
Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Branded
7.3 Generics
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Allergan
10.2 Amneal Pharmaceuticals LLC
10.3 Aurobindo Pharma
10.4 Bausch & Lomb Incorporated
10.5 Cadila Pharmaceuticals Ltd.
10.6 Cipla Ltd.
10.7 Dr. Reddy’s Laboratories
10.8 F. Hoffmann-La Roche Ltd.
10.9 GSK plc
10.10 Glenmark Pharma Ltd.
10.11 Lexine Technochem Pvt. Ltd.
10.12 Monarch Pharmaceuticals
10.13 Pfizer Inc.
10.14 Sun Pharmaceutical Industries Ltd.
10.15 Teva Pharmaceutical Industries Ltd.
